rofecoxib has been researched along with Osteosarcoma in 1 studies
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbey, S | 1 |
| Goossens, L | 1 |
| Taverne, T | 1 |
| Cornet, J | 1 |
| Choesmel, V | 1 |
| Rouaud, C | 1 |
| Gimeno, G | 1 |
| Yannic-Arnoult, S | 1 |
| Michaux, C | 1 |
| Charlier, C | 1 |
| Houssin, R | 1 |
| Hénichart, JP | 1 |
1 other study available for rofecoxib and Osteosarcoma
| Article | Year |
|---|---|
Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor.
Topics: Animals; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; | 2002 |